
In a recent interview, Timothy Fairbairn, Ph.D., and Fatima Rodiguez, M.D., discussed new research findings, recently presented at the American Heart Association (AHA) conference, showing the value of AI-powered quantification of plaque burden from CCTA exams for predicting adverse cardiovascular outcomes.






























